KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) FCF Margin (2016 - 2025)

Historic FCF Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to 10.93%.

  • Vertex Pharmaceuticals' FCF Margin fell 59700.0% to 10.93% in Q4 2025 from the same period last year, while for Dec 2025 it was 26.61%, marking a year-over-year increase of 337800.0%. This contributed to the annual value of 26.61% for FY2025, which is 337800.0% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' FCF Margin stood at 10.93%, which was down 59700.0% from 37.04% recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' FCF Margin peaked at 49.47% during Q2 2022, and registered a low of 144.49% during Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' FCF Margin averaged around 25.45%, with its median value being 40.58% (2022).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' FCF Margin tumbled by -1876000bps in 2024, and later soared by 1757700bps in 2025.
  • Vertex Pharmaceuticals' FCF Margin (Quarter) stood at 45.03% in 2021, then increased by 1bps to 45.37% in 2022, then tumbled by -85bps to 7.01% in 2023, then soared by 141bps to 16.9% in 2024, then crashed by -35bps to 10.93% in 2025.
  • Its FCF Margin was 10.93% in Q4 2025, compared to 37.04% in Q3 2025 and 31.28% in Q2 2025.